The first new Alzheimer’s drug in nearly 20 years has received approval from the Food and Drug Administration.

That’s the good news. The second factor is cost, which is raising concerns for patients and payers, especially Medicare.

biogens aduhelm one is expected Annual price tag of $56,000.

Get Granthshala Business on the go by clicking here

That hefty price tag would massively drive up Medicare premiums, and some patients who have been prescribed the drug could face reimbursements of about $11,500 annually, according to a research report published Thursday by the Kaiser Family Foundation.

Because Aduhelm is not a cure, patients may have to bear these annual out-of-pocket costs for years to come.

FDA approves Biogen Alzheimer’s drugZ

Alzheimer’s disease is estimated to affect 6 million Americans, most of whom are 65 years of age and older and therefore eligible for Medicare.

anchorSecuritylastchangechange %
BIIBBiogen, Inc.414.71+7.77+1.91%

As an intravenously-infused drug administered by physicians, EduHelm would be covered under Medicare Part B, which Commonly FDA-approved physician-administered drugs include which are appropriate and necessary for the individual patient.

People making decisions at the Center for Medicare and Medicaid Services may choose to do the following: National Coverage Determination Process Which may set certain limits on the terms of Medicare coverage for Aduhelm based on the clinical effectiveness of the drug.